Biotech Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests
NewsDealsSocialBlogsVideosPodcasts
Gilead to Acquire Genhouse in $1.5B+ Deal to Accelerate Synthetic Lethality
Acquisition

Gilead to Acquire Genhouse in $1.5B+ Deal to Accelerate Synthetic Lethality

BioWorld (Citeline) – Featured Feeds
BioWorld (Citeline) – Featured Feeds
•February 18, 2026
BioWorld (Citeline) – Featured Feeds
BioWorld (Citeline) – Featured Feeds•Feb 18, 2026
0

Participants

Genhouse

Genhouse

target

Deal Summary

Gilead Sciences announced a deal to acquire Genhouse for over $1.5 billion, aiming to strengthen its synthetic lethality oncology pipeline. The acquisition brings Genhouse’s portfolio of synthetic lethality drug candidates and technology into Gilead’s pipeline, underscoring its commitment to precision oncology.

0

Comments

Want to join the conversation?

Loading comments...